Shi L - Search Results

1

Evaluation of pharmacist-led medication reconciliation at county hospitals in China: A multicentre, open-label, assessor-blinded, nonrandomised controlled study.

Fu M, Zhu Y, Wei G, Yu A, Chen F, Tang Y, Wang Z, Wang G, Liu Q, Zhong C, Liu J, Zhong J, Tian P, Li D, Li X, Shi L, Guan X. Fu M, et al. Among authors: shi l. J Glob Health. 2024 Apr 12;14:04058. doi: 10.7189/jogh.14.04058. J Glob Health. 2024. PMID: 38602274 Free PMC article. Clinical Trial.

2

An analysis of China's national essential medicines policy.

Guan X, Liang H, Xue Y, Shi L. Guan X, et al. Among authors: shi l. J Public Health Policy. 2011 Aug;32(3):305-19. doi: 10.1057/jphp.2011.34. Epub 2011 May 26. J Public Health Policy. 2011. PMID: 21614030

3

Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.

Xin XX, Guan XD, Shi LW. Xin XX, et al. Orphanet J Rare Dis. 2016 Jun 6;11(1):74. doi: 10.1186/s13023-016-0454-7. Orphanet J Rare Dis. 2016. PMID: 27266878 Free PMC article.

4

Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China.

Xin XX, Zhao L, Guan XD, Shi LW. Xin XX, et al. Among authors: shi lw. Chin Med J (Engl). 2016 Jun 20;129(12):1387-93. doi: 10.4103/0366-6999.183425. Chin Med J (Engl). 2016. PMID: 27270531 Free PMC article.

5

The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China.

Guo Z, Guan X, Shi L. Guo Z, et al. Among authors: shi l. BMC Health Serv Res. 2017 Nov 13;17(1):723. doi: 10.1186/s12913-017-2698-x. BMC Health Serv Res. 2017. PMID: 29132361 Free PMC article.

6

Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015.

Wushouer H, Tian Y, Guan XD, Han S, Shi LW. Wushouer H, et al. PLoS One. 2017 Dec 27;12(12):e0190314. doi: 10.1371/journal.pone.0190314. eCollection 2017. PLoS One. 2017. PMID: 29281716 Free PMC article.

7

The effect of the implementation of low price medicine policy on medicine price in China: A retrospective study.

Guan X, Yang M, Man C, Tian Y, Shi L. Guan X, et al. Among authors: shi l. Int J Health Plann Manage. 2018 Apr 30. doi: 10.1002/hpm.2537. Online ahead of print. Int J Health Plann Manage. 2018. PMID: 29709071

8

Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease.

Dong P, Hu H, Guan X, Ung COL, Shi L, Han S, Yu S. Dong P, et al. Among authors: shi l. Chin Med. 2018 Jun 14;13:28. doi: 10.1186/s13020-018-0185-x. eCollection 2018. Chin Med. 2018. PMID: 29946348 Free PMC article.

9

Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.

Guan X, Tian Y, Ross-Degnan D, Man C, Shi L. Guan X, et al. Among authors: shi l. BMJ Open. 2018 Jul 16;8(7):e022328. doi: 10.1136/bmjopen-2018-022328. BMJ Open. 2018. PMID: 30012792 Free PMC article.

10

A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals.

Guan X, Hu H, Man C, Shi L. Guan X, et al. Among authors: shi l. Int J Equity Health. 2018 Oct 19;17(1):158. doi: 10.1186/s12939-018-0870-5. Int J Equity Health. 2018. PMID: 30340587 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,418 results

Search Page

Filters